| 2.04 0.11 (5.7%) | 04-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.73  |
1-year : | 3.04 |
| Resists | First : | 2.34 |
Second : | 2.6 |
| Pivot price | 2.19 |
|||
| Supports | First : | 1.9 | Second : | 1.58 |
| MAs | MA(5) : | 2.06 |
MA(20) : | 2.24 |
| MA(100) : | 2.38 |
MA(250) : | 3.48 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 10.6 |
D(3) : | 17.8 |
| RSI | RSI(14): 41 |
|||
| 52-week | High : | 8.22 | Low : | 1.42 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CHRS ] has closed above bottom band by 27.5%. Bollinger Bands are 8.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.06 - 2.07 | 2.07 - 2.09 |
| Low: | 1.9 - 1.92 | 1.92 - 1.93 |
| Close: | 2.02 - 2.04 | 2.04 - 2.06 |
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Thu, 18 Apr 2024
When Will Coherus BioSciences, Inc. (NASDAQ:CHRS) Breakeven? - Simply Wall St
Wed, 20 Mar 2024
Coherus Biosciences Stock: Dumping One Drug But Showing Promise With Another (NASDAQ:CHRS) - Seeking Alpha
Sat, 16 Mar 2024
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 14 Mar 2024
Coherus stock gains amid oncology focus, job cuts (NASDAQ:CHRS) - Seeking Alpha
Wed, 13 Mar 2024
Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite Net Losses - GuruFocus.com
Wed, 13 Mar 2024
Coherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 114 (M) |
| Shares Float | 104 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 77.4 (%) |
| Shares Short | 23,450 (K) |
| Shares Short P.Month | 24,200 (K) |
| EPS | -2.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.73 |
| Profit Margin | -92.5 % |
| Operating Margin | -98.8 % |
| Return on Assets (ttm) | -21.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 101.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.26 |
| EBITDA (p.s.) | -1.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -175 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | -0.81 |
| PEG Ratio | 0.1 |
| Price to Book value | -1.19 |
| Price to Sales | 0.9 |
| Price to Cash Flow | -1.33 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|